Could a Low-Dose seizure drug quiet Parkinson's psychosis?
NCT ID NCT05824728
First seen Oct 31, 2025
Summary
This study tests whether AGB101, a low-dose seizure medication, can reduce hallucinations and delusions in people with Parkinson's disease. About 30 adults aged 40-85 will take the drug and a placebo at different times, with brain scans and questionnaires to track changes. The goal is to see if it safely eases psychotic symptoms without curing the underlying disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE PSYCHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.